Octagon Capital Advisors »

Cytokinetics shares owned by Octagon Capital Advisors

Quarter-by-quarter ownership of Cytokinetics (CYTK) shares owned by Octagon Capital Advisors from 13F filings

Historical chart of Octagon Capital Advisors investment in Cytokinetics

Tip: Access up to 7 years of quarterly data

All positions including Cytokinetics held by Octagon Capital Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Cytokinetics by Octagon Capital Advisors

Quarter filed Position value Share count Share price at filing
2023-12-31 $9.7M 116k 83.49

More positions owned by Octagon Capital Advisors

Apellis Pharmaceuticals (APLS)
Cymabay Therapeutics
Verona Pharma Sponsored Ads (VRNA)
Insmed Com Par $.01 (INSM)
Arcus Biosciences Incorporated (RCUS)
Bridgebio Pharma (BBIO)
Celldex Therapeutics Com New (CLDX)
Roivant Sciences SHS (ROIV)
Alpine Immune Sciences (ALPN)
Structure Therapeutics Sponsored Ads (GPCR)
Centessa Pharmaceuticals Sponsored Ads (CNTA)
An2 Therapeutics (ANTX)
Miragen Therapeutics (VRDN)
Immunovant (IMVT)
Dyne Therapeutics (DYN)

View all positions for Octagon Capital Advisors

Top funds holding Cytokinetics

Vanguard Group
Wellington Management Company
Caption Management
T. Rowe Price Associates
Henderson Group
Boxer Capital
Citadel Advisors
Partner Fund Management
Logos Global Management
Lord, Abbett & Co
Millennium Management
Artal Group
Barclays
Gts Securities
Goldman Sachs Group

View all funds holding Cytokinetics